5 New Stock Picks of Billionaire Ken Fisher
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a biotech firm that develops therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases.
Bridgebio Pharma Inc. (BBIO)
Get Email Alerts Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 26,620,991 | $1,247,726 | 3.46% | |
| 2. | Perceptive Advisors Joseph Edelman | 7,756,928 | $363,567 | 5.27% | |
| 3. | Hillhouse Capital Management Lei Zhang | 5,362,014 | $251,318 | 3.28% | |
| 4. | 114,950,000 | $158,746 | +57% | 0.03% | |
| 5. | 80,000,000 | $110,499 | 2.15% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $62.50 | 8,000 | Officer | 300,043 | 2021-02-17 | Filing | |
| $62.50 | 16,000 | Director | 21,000 | 2021-02-17 | Filing | |
| $17.00 | 2,647,100 | Large Shareholder | 36,900,661 | 2019-07-01 | Filing | |
| $17.00 | 14,000 | Officer | 14,000 | 2019-07-01 | Filing | |
| $17.00 | 7,000 | Officer | 180,767 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $53.23 | 13,777 | Officer, Director | 45,860 | 2021-08-04 | Filing | |
| $60.47 | 3,450,000 | 31,060,971 | 2021-02-17 | Filing | ||
| $69.94 | 8,563 | Officer | 12,568 | 2020-12-28 | Filing | |
| $69.34 | 10,937 | Officer | 21,131 | 2020-12-28 | Filing | |
| $65.48 | 45,473 | Officer, Director | 45,860 | 2020-12-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 70,696 | $3,313,521 | 0% | |
| 2. | 31,060,971 | $1,455,828 | 7.26% | |
| 3. | 22,982 | $1,077,166 | 0% | |
| 4. | 10,141,311 | $475,323 | 0.01% | |
| 5. | 9,435,412 | $442,238 | 0.01% |
News See All
Hedge Funds Are Piling Into BridgeBio Pharma, Inc. (BBIO)
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million holdings threshold to file a report that shows their positions at the end of every quarter.
5 Best Biotech Stocks to Buy According to Joseph Edelman’s Perceptive Advisors
In this article, we will discuss the 5 best biotech stocks to buy according to Joseph Edelman's Perceptive Advisors based on Q2 holdings of the fund.
Should You Be Tempted To ‘Sell’ BridgeBio Pharma (BBIO) Stock?
Baron Opportunity Fund recently published its second-quarter commentary – a copy of which can be downloaded here.
10 Best Stocks to Invest In According to Chinese Billionaire Lei Zhang
In this article, we will discuss 10 best stocks to invest in according to Chinese billionaire Lei Zhang based on Q1 holdings of the fund.
Baron Funds: “We Retain Conviction in BridgeBio (BBIO)”
Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2021 investor letter – a copy of which can be downloaded here.
Hedge Funds Are Crazy About BridgeBio Pharma, Inc. (BBIO)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
10 Best Stocks to Buy According to DiDi (NYSE: DIDI)’s Early Investor Billionaire Zhang Lei
In this article we will take a look at the 10 best stocks to buy according to billionaire Zhang Lei, who was an early investor in DiDi Global Inc - ADR (NYSE: DIDI).
Is BridgeBio Pharma Inc. (BBIO) A Smart Long-Term Buy?
Baron Funds, an asset management firm, published its “Baron Health Care Fund” first quarter 2021 investor letter – a copy of which can be downloaded here.
Is BBIO Stock A Buy or Sell?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Billionaire Hedge Funds
